[ad_1]
SAN FRANCISCO — Investors attending the J.P. Morgan Healthcare Conference packed themselves into a hotel meeting room Monday to hear Revolution Medicines CEO Mark Goldsmith explain why Merck — or some other pharma buyer — should pay $30 billion or more to acquire the developer of targeted cancer drugs.
Goldsmith didn’t specifically address the media reports of an imminent deal, of course. It was the subtext of his remarks, delivered in a dry, matter-of-fact style, that spoke much more loudly.
J.P. Morgan analyst Brian Cheng, the host of the session, gave it a good try. “Do you see yourself building something bigger?” he asked Goldsmith. “How do you balance your goal in building a bigger company versus taking strategic transactions in front of you?”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
[ad_2]
Source link
